Global Age-Related Macular Degeneration (AMD) Disease Market - Industry Trends and Forecast to 2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,800	240 Pages	Data Bridge Market Research	May, 2022	DAABD17330358

Best Price Guarantee
Price	from $4,800
Length	240 Pages
Publisher	Data Bridge Market Research
Published Date	May, 2022
SKU	DAABD17330358

Global Age-Related Macular Degeneration (AMD) Disease Market - Industry Trends and Forecast to 2029

Global age-related macular degeneration (AMD) disease market is projected to register a CAGR of 8.3% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:
Global Age-Related Macular Degeneration (AMD) Disease Market, By Types (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others) and Distribution Channel (Direct Tender And Retail Sales) Industry Trends and Forecast to 2029

Some of the major factors contributing to the growth of the global age-related macular degeneration (AMD) disease market are:
• Growing geriatric population
• Growing prevalence of macular degeneration
Market Players

The key market players for global age-related macular degeneration (AMD) disease market are listed below:
• REGENXBIO Inc.
• Astellas Pharma
• Ionis Pharmaceutics
• Ocugen Inc.
• Bayer
• Novartis AG
• PIXIUM VISION
• johnson and johnson
• IVERIC bio
• MeiraGTx Limited
• Gensight Biologics
• Adverum Biotechnologies
• Graybug Vision
• Kodiak Sciences
• Genentech, Inc.

1 Introduction: 1.1 Objectives Of The Study; 1.2 Market Definition; 1.3 Overview Of Global Age-related Macular Degeneration (Amd) Disease Market; 1.4 Limitations; 1.5 Markets Covered
2 Market Segmentation: 2.1 Markets Covered; 2.2 Geographical Scope; 2.3 Years Considered For The Study; 2.4 Currency And Pricing; 2.5 Dbmr Tripod Data Validation Model; 2.6 Multivariate Modelling; 2.7 Type Lifeline Curve; 2.8 Primary Interviews With Key Opinion Leaders; 2.9 Dbmr Market Position Grid; 2.10 Market End User Coverage Grid; 2.11 Vendor Share Analysis; 2.12 Secondary Sources; 2.13 Assumptions
3 Executive Summary
4 Premium Insights: 4.1 Pestel; 4.2 Porter's Five Forces Model
5 Regulatory Framework
6 Market Overview: 6.1 Drivers; 6.1.1 Rising Prevalence Of Age-related Macular Degeneration; 6.1.2 Increasing Geriatric Population; 6.1.3 Increase In Pipeline Products; 6.1.4 Increase In Strategic Initiative By Key Players; 6.2 Restraints; 6.2.1 High Cost Of Treatment And Procedures; 6.2.2 Lack Of Enough Qualified Professionals; 6.3 Opportunities; 6.3.1 Increasing Research And Development; 6.3.2 Increase In Awareness And Treatment-seeking Rate Of Amd; 6.3.3 Emerging Reimbursement Policies For The Treatment; 6.3.4 Increasing Product Approval For Age-related Macular Degeneration (Amd); 6.4 Challenges; 6.4.1 Limited Access To Treatment; 6.4.2 Stringent Government Regulations For Products
7 Global Age-related Macular Degeneration (Amd) Disease Market, By Type: 7.1 Overview; 7.2 Dry Amd; 7.3 Wet Amd; 7.3.1 Medications; 7.3.2 Anti-vegf Therapy; 7.3.3 Gene Therapy; 7.3.4 Surgery
8 Global Age- Related Macular Degeneration (Amd) Disease Market, By End User: 8.1 Overview; 8.2 Hospitals; 8.3 Specialty Clinics; 8.4 Ambulatory Surgical Centers; 8.5 Home Healthcare; 8.6 Others
9 Global Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel: 9.1 Overview; 9.2 Retail Sales; 9.2.1 Hospital Pharmacies; 9.2.2 Retail Pharmacies; 9.2.3 Others; 9.3 Direct Tender
10 Global Age-related Macular Degeneration (Amd) Disease Market, By Region: 10.1 Overview; 10.2 North America; 10.2.1 U.S.; 10.2.2 Canada; 10.2.3 Mexico; 10.3 Europe; 10.3.1 Germany; 10.3.2 France; 10.3.3 U.K.; 10.3.4 Russia; 10.3.5 Italy; 10.3.6 Spain; 10.3.7 Netherlands; 10.3.8 Switzerland; 10.3.9 Poland; 10.3.10 Turkey; 10.3.11 Austria; 10.3.12 Hungary; 10.3.13 Norway; 10.3.14 Ireland; 10.3.15 Lithuania; 10.3.16 Rest Of Europe; 10.4 Asia-pacific; 10.4.1 China; 10.4.2 Japan; 10.4.3 India; 10.4.4 South Korea; 10.4.5 Australia; 10.4.6 Singapore; 10.4.7 Thailand; 10.4.8 Indonesia; 10.4.9 Philippines; 10.4.10 Malaysia; 10.4.11 Vietnam; 10.4.12 Rest Of Asia-pacific; 10.5 South America; 10.5.1 Brazil; 10.5.2 Argentina; 10.5.3 Peru; 10.5.4 Rest Of South America; 10.6 Middle East & Africa; 10.6.1 South Africa; 10.6.2 Saudi Arabia; 10.6.3 Uae; 10.6.4 Israel; 10.6.5 Egypt; 10.6.6 Kuwait; 10.6.7 Rest Of Middle East & Africa
11 Global Age-related Macular Degeneration (Amd) Disease Market: Company Landscape: 11.1 Company Share Analysis: Global; 11.2 Company Share Analysis: North America; 11.3 Company Share Analysis: Europe; 11.4 Company Share Analysis: Asia-pacific
12 Swot Analysis
13 Company Profile: 13.1 Novartis Ag; 13.1.1 Company Snapshot; 13.1.2 Revenue Analysis; 13.1.3 Company Share Analysis; 13.1.4 Product Portfolio; 13.1.5 Recent Development; 13.1.5.1 Agreement; 13.2 Genentech, Inc.; 13.2.1 Company Snapshot; 13.2.2 Company Share Analysis; 13.2.3 Product Portfolio; 13.2.4 Recent Development; 13.3 Bayer Ag; 13.3.1 Company Snapshot; 13.3.2 Revenue Analysis; 13.3.3 Company Share Analysis; 13.3.4 Product Portfolio; 13.3.5 Recent Development; 13.4 Adverum Biotechnologies, Inc.; 13.4.1 Company Snapshot; 13.4.2 Revenue Analysis; 13.4.3 Product Portfolio; 13.4.4 Recent Development; 13.5 Astellas Pharma Inc.; 13.5.1 Company Snapshot; 13.5.2 Revenue Analysis; 13.5.3 Product Portfolio; 13.5.4 Recent Development; 13.6 Graybug Vision Inc.; 13.6.1 Company Snapshot; 13.6.2 Revenue Analysis; 13.6.3 Product Portfolio; 13.6.4 Recent Development; 13.7 Gensight Biologics; 13.7.1 Company Snapshot; 13.7.2 Revenue Analysis; 13.7.3 Product Portfolio; 13.7.4 Recent Developments; 13.7.4.1 Event; 13.7.4.2 Award; 13.8 Ionis Pharmaceuticals; 13.8.1 Company Snapshot; 13.8.2 Revenue Analysis; 13.8.3 Product Portfolio; 13.8.4 Recent Development; 13.8.4.1 Event; 13.9 Iveric Bio; 13.9.1 Company Snapshot; 13.9.2 Product Portfolio; 13.9.3 Recent Development; 13.10 Johnson &Johnson Services, Inc.; 13.10.1 Company Snapshot; 13.10.2 Revenue Analysis; 13.10.3 Product Portfolio; 13.10.4 Recent Development; 13.10.4.1 Collaboration; 13.11 Kodiak Sciences Inc.; 13.11.1 Company Snapshot; 13.11.2 Product Portfolio; 13.11.3 Recent Development; 13.12 Meiragtx Limited; 13.12.1 Company Snapshot; 13.12.2 Product Portfolio; 13.12.3 Recent Developments; 13.12.3.1 Events; 13.12.3.2 Award; 13.12.3.3 Collaboration; 13.13 Ocugen Inc.; 13.13.1 Company Snapshot; 13.13.2 Product Portfolio; 13.13.3 Recent Developments; 13.13.3.1 Investment; 13.13.3.2 Clinical Trial; 13.14 Pixium Vision; 13.14.1 Company Snapshot; 13.14.2 Revenue Analysis; 13.14.3 Product Portfolio; 13.14.4 Recent Development; 13.14.4.1 Award; 13.15 Regenxbio Inc.; 13.15.1 Company Snapshot; 13.15.2 Product Portfolio; 13.15.3 Recent Developments; 13.15.3.1 Event; 13.15.3.2 Collaboration; 13.15.3.3 Certification
14 Questionnaire
15 Related Reports
List Of Figures: Figure 1 Global Age-related Macular Degeneration (Amd) Disease Market: Segmentation; Figure 2 Global Age-related Macular Degeneration (Amd) Disease Market: Data Triangulation; Figure 3 Global Age-related Macular Degeneration (Amd) Disease Market: Droc Analysis; Figure 4 Global Age-related Macular Degeneration (Amd) Disease Market: Global Vs Regional Market Analysis; Figure 5 Global Age-related Macular Degeneration (Amd) Disease Market: Company Research Analysis; Figure 6 Global Age-related Macular Degeneration (Amd) Disease Market: Multivariate Modelling; Figure 7 Global Age-related Macular Degeneration (Amd) Disease Market: Interview Demographics; Figure 8 Global Age-related Macular Degeneration (Amd) Disease Market: Dbmr Market Position Grid; Figure 9 Global Age-related Macular Degeneration (Amd) Disease Market: End User Coverage Grid; Figure 10 Global Age-related Macular Degeneration (Amd) Disease Market: Vendor Share Analysis; Figure 11 Global Age-related Macular Degeneration (Amd) Disease Market: Segmentation; Figure 12 North America Is Expected To Dominate And Europe Is Growing At The Fastest Pace In Global Age-related Macular Degeneration (Amd) Disease Market In The Forecast Period Of 2022 To 2029; Figure 13 Increase In The Prevalence Of Age-related Macular Degeneration (Amd) And Growing Geriatric Population Are Driving The Global Age-related Macular Degeneration (Amd) Disease Market In The Forecast Period Of 2022 To 2029; Figure 14 Dry Amd Segment Is Expected To Account For The Largest Share Of The Global Age-related Macular Degeneration (Amd) Disease Market In 2022 & 2029; Figure 15 Europe Is The Fastest-growing Market In Global Age-related Macular Degeneration (Amd) Disease Market In The Forecast Period Of 2022 To 2029; Figure 16 Drivers, Restraints, Opportunities, And Challenges Of Global Age-related Macular Degeneration (Amd) Disease Market; Figure 17 Global Age-related Macular Degeneration (Amd) Disease Market: By Type, 2021; Figure 18 Global Age-related Macular Degeneration (Amd) Disease Market: By Type, 2022-2029 (Usd Million); Figure 19 Global Age-related Macular Degeneration (Amd) Disease Market: By Type, Cagr (2022-2029); Figure 20 Global Age-related Macular Degeneration (Amd) Disease Market: By Type, Lifeline Curve; Figure 21 Global Age-related Macular Degeneration (Amd) Disease Market: By End User, 2021; Figure 22 Global Age-related Macular Degeneration (Amd) Disease Market: By End User, 2022-2029 (Usd Million); Figure 23 Global Age-related Macular Degeneration (Amd) Disease Market: By End User, Cagr (2022-2029); Figure 24 Global Age-related Macular Degeneration (Amd) Disease Market: By End User, Lifeline Curve; Figure 25 Global Age-related Macular Degeneration (Amd) Disease Market: By Distribution Channel, 2021; Figure 26 Global Age-related Macular Degeneration (Amd) Disease Market: By Distribution Channel, 2022-2029 (Usd Million); Figure 27 Global Age-related Macular Degeneration (Amd) Disease Market: By Distribution Channel, Cagr (2022-2029); Figure 28 Global Age-related Macular Degeneration (Amd) Disease Market: By Distribution Channel, Lifeline Curve; Figure 29 Global Age-related Macular Degeneration (Amd) Disease Market: Snapshot (2021); Figure 30 Global Age-related Macular Degeneration (Amd) Disease Market: By Region (2021); Figure 31 Global Age-related Macular Degeneration (Amd) Disease Market: By Region (2022 & 2029); Figure 32 Global Age-related Macular Degeneration (Amd) Disease Market: By Region (2021 & 2029); Figure 33 Global Age-related Macular Degeneration (Amd) Disease Market: By Type (2022 & 2029); Figure 34 North America Age-related Macular Degeneration (Amd) Disease Market : Snapshot (2021); Figure 35 North America Age-related Macular Degeneration (Amd) Disease Market : By Country (2021); Figure 36 North America Age-related Macular Degeneration (Amd) Disease Market : By Country (2022 & 2029); Figure 37 North America Age-related Macular Degeneration (Amd) Disease Market : By Country (2021 & 2029); Figure 38 North America Age-related Macular Degeneration (Amd) Disease Market : By Type (2022-2029); Figure 39 Europe Age-related Macular Degeneration (Amd) Disease Market: Snapshot (2021); Figure 40 Europe Age-related Macular Degeneration (Amd) Disease Market: By Country (2021); Figure 41 Europe Age-related Macular Degeneration (Amd) Disease Market: By Country (2022 & 2029); Figure 42 Europe Age-related Macular Degeneration (Amd) Disease Market: By Country (2021 & 2029); Figure 43 Europe Age-related Macular Degeneration (Amd) Disease Market: By Type (2022-2029); Figure 44 Asia-pacific Age-related Macular Degeneration (Amd) Disease Market: Snapshot (2021); Figure 45 Asia-pacific Age-related Macular Degeneration (Amd) Disease Market: By Country (2021); Figure 46 Asia-pacific Age-related Macular Degeneration (Amd) Disease Market: By Country (2022 & 2029); Figure 47 Asia-pacific Age-related Macular Degeneration (Amd) Disease Market: By Country (2021 & 2029); Figure 48 Asia-pacific Age-related Macular Degeneration (Amd) Disease Market: By Type (2022-2029); Figure 49 South America Age-related Macular Degeneration (Amd) Disease Market: Snapshot (2021); Figure 50 South America Age-related Macular Degeneration (Amd) Disease Market: By Country (2021); Figure 51 South America Age-related Macular Degeneration (Amd) Disease Market: By Country (2022 & 2029); Figure 52 South America Age-related Macular Degeneration (Amd) Disease Market: By Country (2021 & 2029); Figure 53 South America Age-related Macular Degeneration (Amd) Disease Market: By Type (2022-2029); Figure 54 Middle East & Africa Age-related Macular Degeneration (Amd) Disease Market: Snapshot (2021); Figure 55 Middle East & Africa Age-related Macular Degeneration (Amd) Disease Market: By Country (2021); Figure 56 Middle East & Africa Age-related Macular Degeneration (Amd) Disease Market: By Country (2022 & 2029); Figure 57 Middle East & Africa Age-related Macular Degeneration (Amd) Disease Market: By Country (2021 & 2029); Figure 58 Middle East & Africa Age-related Macular Degeneration (Amd) Disease Market: By Type (2022-2029); Figure 59 Global Age-related Macular Degeneration (Amd) Disease Market: Company Share 2021 (%); Figure 60 North America Age-related Macular Degeneration (Amd) Disease Market: Company Share 2021 (%); Figure 61 Europe Age-related Macular Degeneration (Amd) Disease Market: Company Share 2021 (%); Figure 62 Asia-pacific Age-related Macular Degeneration (Amd) Disease Market: Company Share 2021 (%)